Venom-derived peptides like scorpion chlorotoxin and lizard exendin-4 are being engineered as precision guides to deliver drugs and imaging agents directly to diseased tissues.
Chlorotoxin & exendin-4the two most promising venom-derived peptides for targeted drug delivery, from scorpion and Gila monster venoms respectively
What the researchers found
This review synthesizes research on using venom-derived peptides as targeting agents for drug delivery. Chlorotoxin (from scorpion venom) and exendin-4 (from Gila monster venom) have shown the most promise. Venom peptides have been incorporated into nanoparticles and bioconjugates to deliver therapeutic and diagnostic agents, primarily targeting cancer and nervous system conditions. Their evolutionary refinement provides high potency and specificity for human biomolecules.
Why it matters
Many drugs fail because they can't reach their target or cause too many side effects elsewhere. Venom peptides, shaped by millions of years of evolution to precisely target specific biological molecules, offer a natural solution. Harnessing these peptides for drug delivery could dramatically improve treatment precision while reducing toxicity.
The numbers in context
Multiple venom-derived peptides reviewed · chlorotoxin (scorpion) and exendin-4 (lizard) highlighted as most promising · nanoparticle and bioconjugate delivery systems
How the study worked
Comprehensive literature review of research on venom-derived peptides used in targeted drug delivery systems, covering natural and modified peptide variants, nanoparticle and bioconjugate platforms, and applications in therapeutics and diagnostics.
Who was studied
Review of published research; no direct subjects
What this study cannot tell us
As a review, this synthesizes existing research without presenting new data. Most of the delivery systems discussed are still in preclinical or early development stages. The translation from lab-based targeting demonstrations to clinical drug delivery products remains challenging.
How to read the evidence
This is a narrative review synthesizing the current state of venom peptide drug delivery research. It provides a broad overview of the field without presenting new experimental data, representing a synthesis of mostly preclinical evidence.
When this study was published
Published in 2025, this is a current review capturing the latest developments in venom peptide-based drug delivery, a rapidly evolving field.
The bigger picture
Targeted drug delivery is a cornerstone of modern pharmaceutical development. Venom peptides occupy a unique niche — they offer the targeting precision of antibodies but in a much smaller, more versatile molecular format. As peptide engineering and nanotechnology advance, these natural toxins-turned-therapies could become standard components of precision medicine, particularly for hard-to-treat cancers and neurological conditions.
Questions still open
- Can venom peptide-guided delivery systems achieve the same targeting precision in humans as demonstrated in preclinical models?
- Will immunogenicity (immune reactions to venom-derived peptides) limit repeated clinical use of these delivery systems?
- Could AI-driven peptide design improve upon natural venom peptides for even better targeting specificity?
Common questions
Why are venom peptides good at targeting specific tissues?
Are any venom-derived peptide drugs already approved for human use?
Read the original research
Targeting with toxins: an overview of venom peptides in drug delivery.
International journal of pharmaceutics, 685, 126193
Citation
Mazurs, Austris; Mauriņa, Baiba; Bandere, Dace; Logviss, Konstantīns. (2025). Targeting with toxins: an overview of venom peptides in drug delivery.. International journal of pharmaceutics, 685, 126193. https://doi.org/10.1016/j.ijpharm.2025.126193